Fig. 5.

TFF3 deficiency in mice does not increase susceptibility to DSS colitis. a Change in initial body weight, b disease activity index scores and c colon lengths following DSS administration in cohorts of co-housed WT versus Tff3KO mice. d Gefitinib treatment protocol during DSS administration. e Change in initial body weight, f disease activity index, g colon lengths and h colonic Egf mRNA transcript levels at time of sacrifice in WT vs. Tff3KO cohoused mice following 2.5% DSS treatment with or without Gefitinib. Means ± SE of 8, 9 or 10 mice/group and results of two-way ANOVA analyses are shown